One objective underlying development of these guidelines was to identify research gaps regarding the management of cancer treatment–related hot flashes.
Incorporating 2 standardized documents into the process for supportive care measures improved outcomes for patients receiving HD-MTX.
Retrospective analysis demonstrates the value in distinguishing between these conditions to salvage chemotherapy and/or targeted therapy dose in patients with cancer.
Benzodiazepines are widely used to treat a variety of conditions including anxiety disorders, insomnia and seizures.
Investigators aimed to compare the prevalence and likelihood of opioid use and misuse among cancer survivors and those without cancer.
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
A literature search of new studies clarifies, refutes, and expands on previous recommendations for managing new and established CIPN in patients treated with cytotoxic agents.
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
In addition to being common yet serious diseases, both cancer and fibromyalgia bring a high burden of physical pain and negative effects on mental health.
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Vitamin D may be used to reduce the risk of immune checkpoint inhibitor-related colitis, as well as ulcerative colitis and graft-vs-host disease.
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
The level of control of acute-phase CIV in pediatric patients was lower in this study than has been reported for adult patients; control of delayed-phase CIV is also poor.
The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
This phase 2 study used a crossover design in which study medication and placebo were administered to all patients in cycles A and B of chemotherapy, respectively.
Researchers aimed to determine whether the addition of radiotherapy was associated with a risk for adverse events among patients treated with ICIs.
Prescription drug monitoring programs that aim to prevent opioid misuse may be affecting patients with cancer who need pain management.
Expertise in the use of nonpharmacologic pain management techniques and therapies allow masters-prepared social workers to be an integral member of a multidisciplinary cancer care team.
Although olanzapine shows promise as a treatment for chronic nausea and vomiting in patients with advanced cancer, larger studies are needed.
Mortality lower despite common opioid prescriptions for cancer-related pain.
A prospective study demonstrated this treatment is an option for patients undergoing chemoradiation for gynecologic cancers who are at risk of late-onset CINV or noncompliance with oral therapy.
A randomized study determined the efficacy of adding peppermint essential oil to a cool wash cloth to ease nausea associated with chemotherapy.
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.
A 3-cycle Plan-Do-Study-Act intervention resulted in increased nurse and physician education on mucositis and a nurse-driven protocol that reduced MBI-LCBIs by 25%.
Higher proportions of patients receiving olanzapine reported only mild or no nausea compared with patients receiving placebo.
Treatment regimens including immunomodulatory agents or proteasome inhibitors could lead to development of peripheral neuropathy.
This study addressed the dearth of information on the incidence of psychiatric disorders related to corticosteroid-containing treatment in patients with hematologic malignancies.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Busulfan usage, high ferritin levels prior to HSCT, and treatment with some antibody-drug conjugates were deemed to be risk facts for VOD/SOS.
Some studies have found a link between intestinal microbiota composition and development of acute graft-versus-host disease.
Nonwhite race, poor acute phase nausea control, and treatment with cisplatin were all associated with higher self-reported nausea severity scores.
Patients taking opioids for cancer-related pain at outpatient supportive pain consultations may be at higher risk for aberrant opioid and drug use behavior.
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
An overview of the potential immune-related adverse events that can arise from treatment with checkpoint inhibitors.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.